Dr. William Tse

Dr. William Tse |Clyto Access

Chief, University of Louisville Hospital, USA

Editor-in-Chief

Expertise: Blood and Bone Marrow Transplantation, Oncology, Internal Medicine

Bio:
Dr. William Tse is Professor of Medicine and attending physician at James Graham Brown Cancer Center, University of Louisville School of Medicine.  Dr. Tse received his medical degree from Sun Yat-Sen University School of Medicine, Guangzhou, China. He completed his internal medicine training at Long Island Jewish Medical Center/Albert Einstein College of Medicine and Medical Oncology/Bone Marrow Transplantation Fellowship at The Fred Hutchinson Cancer Research Center/University of Washington School of Medicine.  Along with his clinical training, he received his laboratory research training at the Ontario Cancer Institute/Princess Margaret Hospital and The Hospital for Sick Children, University of Toronto, Canada.
He received the Top Cancer Doctors Award from United States of America in 2015 by Newsweek Magazine, Top Medical Oncologist Award in 2014; Leadership Development Program Award from American Society of Clinical Oncology in 2012; T. Franklin Williams Scholar Award from American Association of Specialty Professors in 2006,and many other awards. 

He also actively serves on multiple journals’ editorial boards. Currently, he holds the Marion F. Beard endowed Chair of Hematology and is Chief of the Division of Blood and Marrow Transplantation, James Graham Brown Cancer Center, University of Louisville Hospital, Louisville, KY. Dr. Tse is focused on Blood and Bone Marrow Transplantation, clinical and translational cancer research for hematopoietic malignancies including pre-clinical models for developmental therapeutics, cancer biology, and cancer cell signaling network profiles.

He identified a novel co-factor, AF1q, interacts with T-cell-factor (TCF) associated transcriptional machinery that dysregulatesthe Wnt signaling pathway. At the meantime, the AF1q co-factor also simultaneously activates the Notch and PDGF/Stat3 signaling pathways that are also associated with cancer and leukemic stem cells behaviors. Tse’s work demonstrates an innovative multi-targeted therapeutic approach for a subgroup of leukemia and solid cancer patients that have the AF1q-centered aberrant signaling pathways.

Related Journals & Conferences :

Global Forum on Transplantation Research and Technologies

International Journal of Transplantation Research and Technology